Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of VEAB Ventilation Entreprenad
Mandate

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of VEAB Ventilation Entreprenad

June 28, 2021 Employment and Benefits M&A Real Estate and Construction Banking and Finance

Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of Ventilation Entreprenad VEAB, Veab Ventilation Entreprenad i Kristianstad, VEAB Ventilation Entreprenad I Helsingborg, Styr Entreprenad i Malmö and Energi & Klimatteknik i Tygelsjö.

The companies provide contracting services related to ventilation as well as service on real estate technical installations, and are based in Skåne. Together, the companies have a turnover of approximately SEK 370 million. The transaction is subject to customary regulatory approvals.

Vinge’s team consisted of partner Christina Kokko together with Karl Klackenberg, Hannah Kajlinger and Carl Fredrik Wachtmeister (M&A), Isak Willborg (Construction), Elin Broman (Employment), Karl-Gustaw Tobola (Financing) and Frida Ställborn (Real Estate).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025